1. Home
  2. FGEN vs GRCE Comparison

FGEN vs GRCE Comparison

Compare FGEN & GRCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FGEN
  • GRCE
  • Stock Information
  • Founded
  • FGEN 1993
  • GRCE 2002
  • Country
  • FGEN United States
  • GRCE United States
  • Employees
  • FGEN N/A
  • GRCE N/A
  • Industry
  • FGEN Biotechnology: Pharmaceutical Preparations
  • GRCE
  • Sector
  • FGEN Health Care
  • GRCE
  • Exchange
  • FGEN Nasdaq
  • GRCE NYSE
  • Market Cap
  • FGEN 34.5M
  • GRCE 30.9M
  • IPO Year
  • FGEN 2014
  • GRCE N/A
  • Fundamental
  • Price
  • FGEN $0.49
  • GRCE $3.33
  • Analyst Decision
  • FGEN
  • GRCE
  • Analyst Count
  • FGEN 0
  • GRCE 0
  • Target Price
  • FGEN N/A
  • GRCE N/A
  • AVG Volume (30 Days)
  • FGEN 1.0M
  • GRCE 72.9K
  • Earning Date
  • FGEN 02-24-2025
  • GRCE 02-14-2025
  • Dividend Yield
  • FGEN N/A
  • GRCE N/A
  • EPS Growth
  • FGEN N/A
  • GRCE N/A
  • EPS
  • FGEN N/A
  • GRCE N/A
  • Revenue
  • FGEN $180,015,000.00
  • GRCE N/A
  • Revenue This Year
  • FGEN $21.91
  • GRCE N/A
  • Revenue Next Year
  • FGEN N/A
  • GRCE N/A
  • P/E Ratio
  • FGEN N/A
  • GRCE N/A
  • Revenue Growth
  • FGEN 16.15
  • GRCE N/A
  • 52 Week Low
  • FGEN $0.18
  • GRCE $2.13
  • 52 Week High
  • FGEN $2.93
  • GRCE $4.97
  • Technical
  • Relative Strength Index (RSI)
  • FGEN 46.98
  • GRCE N/A
  • Support Level
  • FGEN $0.46
  • GRCE N/A
  • Resistance Level
  • FGEN $0.51
  • GRCE N/A
  • Average True Range (ATR)
  • FGEN 0.05
  • GRCE 0.00
  • MACD
  • FGEN -0.01
  • GRCE 0.00
  • Stochastic Oscillator
  • FGEN 21.25
  • GRCE 0.00

About FGEN FibroGen Inc

FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.

About GRCE GRACE THERAPEUTICS INC

Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.

Share on Social Networks: